 ROCKVILLE, Md., May 14, 2021 PRNewswire -- RegeneRx Biopharmaceuticals, Inc. OTCQB: RGRX RegeneRx, a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted a press release from its U.S. joint venture, ReGenTree LLC, on its website pursuant to the completed data analysis of its Phase 3 clinical trial ARISE-3 with RGN-259 for the treatment of dry eye syndrome, as well as the results of pooling patient data from all three Phase 3 dry eye trials ARISE-1, ARISE-2 and ARISE-3 comprising approximately 1,500 patients. 